- Home
- SBET vs ZYME Comparison
SBET vs ZYME Comparison
Compare SBET & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SBET | ZYME |
|---|---|---|
| Founded | 1995 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 2025 | 2022 |
Fundamental Metrics
Financial Performance| Metric | SBET | ZYME |
|---|---|---|
| Price | $7.14 | $27.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | $18.71 | ★ $38.90 |
| AVG Volume (30 Days) | ★ 6.3M | 522.6K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | N/A | ★ N/A |
| Revenue | $28,055,000.00 | ★ $105,965,000.00 |
| Revenue This Year | $109.16 | $180.13 |
| Revenue Next Year | $14.66 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 666.04 | 38.87 |
| 52 Week Low | $0.19 | $10.69 |
| 52 Week High | $124.12 | $28.49 |
Technical Indicators
Market Signals| Indicator | SBET | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 53.62 | 63.62 |
| Support Level | $6.05 | $22.28 |
| Resistance Level | $8.34 | $27.35 |
| Average True Range (ATR) | 0.38 | 1.04 |
| MACD | 0.07 | 0.18 |
| Stochastic Oscillator | 73.29 | 91.56 |
Price Performance
Historical ComparisonAbout SBET SharpLink Gaming Ltd.
SharpLink Gaming Inc is one of the world's largest publicly traded companies to adopt ETH as its primary treasury reserve asset - a move that aligns the Company with the future of digital capital and gives investors direct exposure to Ethereum, the world's smart-contract platform and second largest digital asset.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.